History of Changes for Study: NCT00794417

A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Pa Carcinoma

Latest version (submitted November 13, 2020) on ClinicalTrials.gov

- A study version is represented by a row in the table.
- Select two study versions to compare. One each from columns A and B.
- Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The S applies to the Protocol section of the study.
- Click "Compare" to do the comparison and show the differences.
- Select a version's Submitted Date link to see a rendering of the study for that version.
- The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study v
- Hover over the "Recruitment Status" to see how the study's recruitment status changed.
- Study edits or deletions are displayed in ~~red~~.
- Study additions are displayed in green.

Mylan
IPR
U.S.
E

Study Record Versions

Version	A	B	Submitted Date	Changes
1	◉	◉	November 19, 2008	None (earliest Version on record)

Version	A	B	Submitted Date	Changes
3	○	○	November 25, 2009	Study Status, Contacts/Locations, Conditions and Sponsor/Collaborators
4	○	○	January 6, 2010	Contacts/Locations and Study Status
5	○	○	July 19, 2010	Contacts/Locations and Study Status
6	○	○	January 5, 2011	Study Status
7	○	○	January 21, 2011	Recruitment Status, Study Status and Contacts/Locations
8	○	○	February 11, 2011	Study Status
9	○	○	February 16, 2011	Study Design and Study Status
10	○	○	April 17, 2011	Study Status
11	○	○	May 27, 2011	Arms and Interventions and Study Status
12	○	○	January 6, 2012	Recruitment Status, Study Status, Sponsor/Collaborators and Contacts/Locations
13	○	○	August 30, 2012	Study Status ▶ Results Submission Events
14	○	○	November 13, 2020	Recruitment Status, Study Status, Outcome Measures, Arms and Interventions, Mo Design, Study Description, Adverse Events, Baseline Characteristics, Participant Flo and Study Identification

Compare

Comparison Format: ◉ Merged ○ Side-by-Side

Scroll up to access the controls

Study NCT00794417
Submitted Date: November 19, 2008 (v1)

Study Identification

Unique Protocol ID:	VGFT-ST-0708
Brief Title:	A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplat Advanced Carcinoma
Official Title:	A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed With Advanced Carcinoma
Secondary IDs:	TCD10767

Study Status

Record Verification:	November 2008
Overall Status:	Recruiting
Study Start:	September 2008
Primary Completion:	September 2010 [Anticipated]
Study Completion:	October 2010 [Anticipated]
First Submitted:	November 19, 2008
First Submitted that Met QC Criteria:	November 19, 2008
First Posted:	November 20, 2008 [Estimate]
Last Update Submitted that Met QC Criteria:	November 19, 2008
Last Update Posted:	November 20, 2008 [Estimate]

Sponsor/Collaborators

Sponsor:	Regeneron Pharmaceuticals
Responsible Party:	
Collaborators:	Sanofi

Oversight

U.S. FDA-regulated Drug:	
U.S. FDA-regulated Device:	
Data Monitoring:	No

Study Description

Brief Summary:	The purpose of the study is to determine whether the combination of aflibercept, p is safe and effective.
Detailed Description:	The study will be conducted in two phases. In phase 1, patients with advanced ca doses of aflibercept in combination with approved doses of pemetrexed and cispl phase 1 is to determine the safest dose of the combined study medications. This administered to patients with previously untreated non-small cell lung cancer in p portion of the study will determine if the combination is effective in treating non-sr

Conditions

Conditions:	Advanced Carcinoma Non-Small Cell Lung Cancer
Keywords:	advanced cancer lung cancer NSCLC Non-small Cell Lung Cancer aflibercept chemotherapy

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 1/Phase 2
Interventional Study Model:	Single Group Assignment
Number of Arms:	1
Masking:	None (Open Label)
Allocation:	N/A
Enrollment:	100 [Anticipated]

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.